RxDoctor Payments Data

Thomas McKean, MD

Psychiatry · Hickory, NCNPI 1841359486

Payments from drug & device makers

$16,421in general payments, 2019–2025

Across 906 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Alkermes, Inc.$1K
  • Bausch Health US, LLC$1K
  • Neurocrine Biosciences, Inc.$1K
  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • plus $8K from 32 others

What the payments were for

  • Food & beverage$16,399100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,421 in reported general payments places this provider in the 90th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$55,315
Medicare patients
108
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl50$69,522
RexultiBrexpiprazole38$53,456
TrintellixVortioxetine Hydrobromide100$52,497
SpravatoEsketamine Hcl43$47,218
LybalviOlanzapine/Samidorphan Malate21$32,448
AuvelityDextromethorphan Hbr/Bupropion22$20,811
Aripiprazole114$14,190
VyvanseLisdexamfetamine Dimesylate16$5,838
Lurasidone Hcl32$5,781
Bupropion XlBupropion Hcl267$5,719
Alprazolam530$4,007
Clonazepam490$3,903
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine121$3,712
Clomipramine Hcl17$3,376
Doxepin Hcl85$3,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$736$69,52250 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$865$58,335116 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,035$53,45638 claims
Johnson & JohnsonSpravato$1,262$47,21843 claims
Alkermes, Inc.Lybalvi$1,456$32,44821 claims
Axsome Therapeutics, Inc.Auvelity$697$20,81122 claims
Lilly USA, LLCOlanzapine$20$1,17560 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →